Hidden hepatitis b risk in cancer immunotherapy under scrutiny
NCT ID NCT06347588
First seen Nov 20, 2025 · Last updated May 23, 2026 · Updated 22 times
Summary
This study watches 60 cancer patients who have a hidden form of hepatitis B (occult infection) to see if immunotherapy treatments cause the virus to become active again. Researchers will use new blood tests to detect early signs of reactivation. The goal is to better understand and predict this risk, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OCCULT HEPATITIS B INFECTION IN CANCER PATIENTS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Irccs San Matteo Pavia
Pavia, PV, 27100, Italy
Conditions
Explore the condition pages connected to this study.